Merck invited to submit a CDF proposal for Merkel cell cancer drug

28 Nov 2017
National Institute for Health and Care Excellence (NICE)

NICE has asked Merck to submit a Cancer Drugs Fund (CDF) proposal for an immunotherapy called avelumab. Avelumab (marketed as Bavencio) was assessed by NICE as a treatment for people who have Merkel cell carcinoma (MCC), a rare type of skin cancer.


Click here to read the 'NICE' news article in full